The purpose of this study is to determine if the type of Fc gamma RIIIa receptor that a
particular patient's immune cells possess influences how they respond to rituximab and other
- A medical data collection survey sheet will be filled out by the patient or doctor with
medical information pertaining to how the patient responded to rituximab and other
monoclonal antibodies for use in this study.
- Blood work will be performed to analyze the blood by molecular technology to find the
kind of Fc gamna RIIIa receptor the patient possess and correlate these findings with
the outcome of treatment with rituximab or other monoclonal antibodies.
- Patients treated with rituximab or other monoclonal antibodies for Waldenstrom's
Steven Treon, MD, MA, PhD
Dana-Farber Cancer Institute